The emerging role of psilocybin and MDMA in the treatment of mental illness
Hartej Gill, Barjot Gill, David C J Chen-Li, Sabine El‐halabi, Nelson B Rodrigues, S. Danielle, Orly Lipsitz, Yena Lee, Joshua D. Rosenblat, Amna Majeed, Rodrigo B. Mansur, Flora Nasri, Roger Ho, Roger S McIntyre
Expert Review of Neurotherapeutics September 21, 2020 DOI: 10.1080/14737175.2020.1826931 (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractPsychedelics like psilocybin and MDMA show promise as a new type of therapy for mental health disorders. Evidence suggests they may work with just one dose, produce rapid effects, and be effective for treatment-resistant conditions, possibly serving as a standalone treatment. More clinical trials are needed to test their safety, tolerability, and effectiveness in real-world patient populations.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Topics | MDMA Psilocybin |
| Keywords | Mental illness Psychiatry Mental health |
| Citations | 62 |
| Key finding | Psychedelics may offer a single-dose, rapid effect model with robust effects for treatment-resistant mental disorders and a potential advantage as a monotherapy. |
Abstract
Psychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates that psychedelics may offer a single-dose, rapid effect model that have robust effects with treatment-resistant mental disorders and a unique advantage as a possible monotherapy for mental illness. Novel clinical trials that evaluate the safety, tolerability, and efficacy in clinically representative populations are warranted.